Inhaled, intranasal, and topical corticosteroid
ATC code: R03BA07 (Mometasone)
Mometasone furoate is a synthetic glucocorticoid with high receptor affinity and low systemic bioavailability via nasal (<0.1%) and inhaled (~11%) routes. Suppresses pro-inflammatory cytokine production and eosinophil trafficking. Strong topical effect on skin – used for moderate dermatoses.
First line
Seasonal and perennial allergic rhinitis in adults and children from 2-3 years (Nasonex from 2). Per ARIA 2020 and SEAIC 2023, intranasal corticosteroids are first-line. Dose: 100-200 µg (2 sprays per nostril) once daily. Effect at 11 hours, full effect at 1-2 weeks. In children 2-11 years, standard dose is 100 µg once daily. Long-term safety on childhood growth confirmed up to 1 year of daily use (Schenkel 2000).
First line
Asthma in adults and adolescents from 12 years. Per 2024, inhaled corticosteroid is controller-therapy cornerstone. Mometasone furoate dose (Asmanex Twisthaler): 200-800 µg/day in 1-2 doses. Strong local effect allows once-daily dosing in mild-to-moderate asthma. Reassess symptoms and spirometry at 4-12 weeks.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
Use when clearly needed. Beclomethasone and budesonide have more pregnancy data.
Compatible. Hale L2. Minimal systemic absorption – negligible milk transfer.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Mometasone is evaluated for the following indications with varying evidence strength: Asthma (evidence tier A), Allergic rhinitis (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of Mometasone (≥ 1 in 100): Epistaxis, Nasal mucosal irritation, Headache, Sore throat, Cough, Nasal candidiasis (rare). See the Safety section for uncommon and serious reactions.
FDA category C. Use when clearly needed. Beclomethasone and budesonide have more pregnancy data.
Compatible. Hale L2. Minimal systemic absorption – negligible milk transfer.
Mometasone is contraindicated in: Hypersensitivity; Active tuberculosis without concurrent antitubercular therapy; Acute bacterial or viral nasal infection (nasal form); Rosacea, perioral dermatitis (topical form). Full list in the Safety section.